Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03125655 · ClinicalTrials.gov registry record

Regulation of Inflammatory Genes in Psoriasis

A clinical trial of Inflammation and Psoriasis, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
13
Enrollment target
1
Study location

NCT03125655: Recruiting study of Inflammation and Psoriasis, sponsored by University of Alabama at Birmingham.

NCT03125655 is a study of Inflammation and Psoriasis that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 13 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03125655, a study of Inflammation and Psoriasis, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
13 participants
Enrollment target
1
Study location

Study Summary

Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers in the severity and management of the disease after further in-depth studies.

Primary Outcome

TNF-alpha , IFN-alpha , IL-6, IL-8, IL-12 , IL-23, IL-4, IL-5 and IL-10

Conditions Studied

Inflammation Psoriasis

Interventions

  • DIAGNOSTIC_TEST Inflammatory markers

Study Locations (1)

Alabama

  • The Kirklin Clinic - Birmingham

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2014-04-22
Est. Completion 2027-04-28
University of Alabama at Birmingham

1,160 total trials

What NCT03125655 shows while recruiting

NCT03125655 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Inflammatory markers is the first listed.

NCT03125655 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT03125655 about?

NCT03125655 is a clinical study titled "Regulation of Inflammatory Genes in Psoriasis". Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers...

What is the current status of trial NCT03125655?

This trial is currently recruiting. The enrollment target is 13 participants. The study started on 2014-04-22. Estimated completion is 2027-04-28.

What conditions does trial NCT03125655 study?

This clinical trial studies the following conditions: Inflammation, Psoriasis.

What interventions are being tested in trial NCT03125655?

The interventions under investigation include: Inflammatory markers (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03125655?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03125655 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03125655's enrollment target sits among peer trials

13 124th of 132 higher than 9 of 132 other Inflammation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

  • NCT04879121 · 13 participants · Phase 2

    Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03125655

Source: ClinicalTrials.gov NCT03125655, the US trial registry maintained by the National Library of Medicine. NCT03125655 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.